Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Nuedexta Trajectory Holding Steady
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 3
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudobulbar affect, emotional lability seen in stroke, traumatic brain injury, Alzheimer’s and other neurodegenerative disorders. Launch has been steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Even modest continued growth should bbeat current sales consensus, our
estimates. We are modestly raising ‘12 and ‘13 sales estimates, especially given flat inventory."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $2.86 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta steady, continued growth, robust peak sales estimate. Nuedexta is AVNR’s drug for pseudobulbar affect, emotional lability seen in stroke, traumatic brain injury, Alzheimer’s and other neurodegenerative disorders. Launch has been steady, and we see new positive trends in long-term care use. Our peak annual sales estimates are $350M US, $300M EU."
"Even modest continued growth should bbeat current sales consensus, our
estimates. We are modestly raising ‘12 and ‘13 sales estimates, especially given flat inventory."
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $2.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Workday (WDAY) to Hold
- Assurant (AIZ) PT Raised to $320 at BMO Capital
- Donaldson Company (DCI) PT Raised to $95 at Stifel
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
